1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6074766CA364D26B5852584EB0075DF07
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-EU-MSL-Excellence-Optimizing-resources-for-European-field-medical-operations?opendocument
18
19opendocument
2018.206.194.161
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Medical Science Liaison

EU MSL Excellence: Optimizing resources for European field medical operations

ID: 5595


Features:

12 Info Graphics

16 Data Graphics

300+ Metrics

7 Narratives


Pages/Slides: 36


Published: 2020


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "EU MSL Excellence: Optimizing resources for European field medical operations"

STUDY OVERVIEW

The country-specific dynamics of a market can play an outsized role in whether or not your products are embraced by thought leaders or shrugged off in favor of established competition. Are you coordinating and staffing your MSL function appropriately for each of your markets?

Best Practices, LLC conducted this EU-focused study to help pharmaceutical leaders seeking reliable field medical resourcing metrics on current MSL deployment operations in the critical European Union (EU) market.

The study provides EU metrics on MSL staffing, travel and entertainment budget, and MSL utilization during the entire product lifecycle. Pharmaceutical leaders will be able to use the research results to see how their MSL resourcing strategies in the EU stack up against industry averages and trends.

Critical MSL resourcing questions addressed in this study include:

  • Staffing levels
  • T&E spend levels
  • MSL utilization during pre-launch, launch, and post-launch

    KEY TOPICS
  • Executive Summary
  • Resourcing MSLs: Staffing, T&E budgets and launch support
KEY METRICS
  • Average number of brands (including both in-line and pre-launch products) supported by each MSL in each of the listed countries – All regions
  • Average number of brands (including both in-line and pre-launch products) supported by each MSL in each of the listed countries – European countries
  • Total number of MSLs staffed in each country; total number of MSLs supporting each therapeutic area – All regions
  • MSL staffing footprint in each of the listed European countries
  • Total number of MSLs staffed in each country per therapeutic area supported
  • Approximate annual total travel and entertainment (T&E) budget allocated to MSLs – All regions
  • Approximate annual total travel and entertainment (T&E) budget allocated to MSLs in each of the listed countries – European countries
  • Additional MSL staffing and T&E budget data from non-target EU countries
  • Total number of staff allocated to each of the listed MSL management and support roles; Europe span of field control
  • Average percentage of “peak MSL team size” assigned to support a product at each phase of the typical product lifecycle – All regions
  • Average percentage of “peak MSL team size” assigned to support a product at each phase of the typical product lifecycle – European countries
  • Interview narrative around MSL knowledge during phase II
  • Effective timing in Europe to bring an MSL on board to support a product in each phase of the product lifecycle
  • Interview narrative around launch success for field medical teams
  • Effective timing to bring an MSL on board to support a product in each phase of the product lifecycle in each of the targeted European countries
SAMPLE KEY FINDINGS
  • Staffing: MSL team size in EU5 markets ranges from a total of 4.6 MSLs in UK (3.4 per TA) up to 8.8 MSLs in Germany (6.4 per TA). On average, companies allot 1 MSL manager per 5.6 MSLs and 1 MSL effectiveness lead per 12.4 MSLs. Companies typically ramp up launch staffing earlier in the lifecycle (phase III -2 years) than in other regions.

METHODOLOGY

Best Practices, LLC engaged 125 Global Medical Affairs and Field Medical Excellence leaders from more than 40 leading pharma and biotech companies in this research through a benchmarking survey. In-depth interviews were conducted with 8 benchmark partners to gain further insights.

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biotech; Manufacturing; Consumer Products; Medical Device; Chemical; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Abbott; Alexion Pharmaceuticals; Allergopharma; Amgen; AstraZeneca; Bayer; Biogen; Bioventus; Boehringer Ingelheim; Celgene; Chiesi; Clovis Oncology; Dr Reddy's Laboratories; Eisai; Galderma; GE Healthcare; Gedeon Richter ; Gilead Sciences; Grifols; Ipsen; Janssen; Kiniksa Pharmaceuticals; Kyowa Kirin; Merck Serono; Merck; Novartis; Pfizer; Rakuten Medical; Roche; Sandoz; Sanofi; Lupin; Shire; Takeda Pharmaceuticals; Sunovion; UCB Pharma; Vertex Pharmaceuticals; Vifor Pharma; ViiV Healthcare

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.